Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDLLfxC 6-month all-oral regimen for rifampicin-resistant pulmonary tuberculosis
ChiCTR2400091867Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Nov 2024
- Modality
- Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of bedaquiline, delamanid, linezolid, levofloxacin and clofazimine in Rifampicin-resistant pulmonary tuberculosis (RR-PTB), sponsored by Huashan Hospital. Primary endpoint: Proportion of participants with favorable outcomes in both treatment and follow-up period. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
bedaquilinedelamanidlinezolidlevofloxacinclofazimine
03
Conditions
Rifampicin-resistant pulmonary tuberculosis (RR-PTB)
Beyond the preview
Go deeper on ChiCTR2400091867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091867.